Morgan Stanley raised the firm’s price target on Solventum (SOLV) to $73 from $60 and keeps an Equal Weight rating on the shares. Solventum, which “had a clean 3Q print,” seems to be navigating a difficult MedTech backdrop relatively well, especially within the core MedSurg business, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOLV: